drugset / Trial / NCT05253495
Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The addition of targeted immunotherapy will be safe and well tolerated and facilitate the reduction of anthracycline exposure while preserving lymphoma disease control in children, adolescents and young adults (CAYA) with mature B-cell non-Hodgkin lymphoma (MB-NHL) and classical Hodgkin lymphoma (cHL).
Timeline
- Start
- 2022-02-01
- Primary completion
- 2027-12-31
- Completion
- 2028-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Doxorubicin | Other / unclassified | — | — |
| Subject | Nivolumab | Monoclonal antibody | — | — |
| Subject | Polatuzumab Vedotin | Other / unclassified | — | — |
| Background | Brentuximab Vedotin | Monoclonal antibody | — | — |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Cytarabine | Small molecule | — | — |
| Background | Dacarbazine | Small molecule | — | — |
| Background | Dexamethasone | Small molecule | — | — |
| Background | Etoposide | Small molecule | — | — |
| Background | Methotrexate | Small molecule | — | — |
| Background | Rituximab | Monoclonal antibody | — | — |
| Background | Vinblastine | Small molecule | — | — |
| Background | Vincristine | Small molecule | — | — |